S294: LONG-TERM SAFETY AND EFFICACY OF CAPLACIZUMAB FOR ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP): THE POST-HERCULES STUDY

S294: LONG-TERM SAFETY AND EFFICACY OF CAPLACIZUMAB FOR ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP): THE POST-HERCULES STUDY

Bibliographic Details
Main Authors:	M. Scully, J. de la Rubia, K. Pavenski, A. Metjian, P. Knöbl, F. Peyvandi, S. Cataland, P. Coppo, J. A. Kremer Hovinga, R. De Passos Sousa, F. Callewaert, S. Gunawardena, J. Lin
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000844068.17291.63

Similar Items

LONG-TERM OUTCOMES OF PATIENTS TREATED WITH CAPLACIZUMAB FOR IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP): THE POST-HERCULES STUDY
by: Özgür Pektaş, et al.
Published: (2022-10-01)

INTEGRATED EFFICACY RESULTS FROM THE PHASE 2 AND PHASE 3 STUDIES WITH CAPLACIZUMAB IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
by: Flora Peyvandi, et al.
Published: (2021-11-01)

THE ROLE OF ADAMTS13 ACTIVITY LEVELS ON DISEASE EXACERBATION OR RELAPSE IN PATIENTS WITH IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA: POST HOC ANALYSIS OF THE PHASE 3 HERCULES AND POST-HERCULES STUDIES
by: Johanna KREMER HOVINGA, et al.
Published: (2023-10-01)

OUTCOMES OF PATIENTS WITH WORSENING ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) DESPITE DAILY THERAPEUTIC PLASMA EXCHANGE IN THE PHASE 3 HERCULES TRIAL
by: M. Scully, et al.
Published: (2020-11-01)

Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpura
by: L. Kaynar, et al.
Published: (2020-10-01)

Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial)
by: Estcourt, L
Published: (2019)

Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura
by: Ashley Hanlon, et al.
Published: (2020-02-01)

Management of immune thrombotic thrombocytopenic purpura with caplacizumab: a Canadian, single-centre, real-world experience
by: Brandon Tse, et al.
Published: (2023-12-01)

Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura
by: Elverdi T, et al.
Published: (2019-04-01)

Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data
by: Eleni Gavriilaki, et al.
Published: (2023-10-01)

Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura
by: Antonella Bruzzese, et al.
Published: (2023-07-01)

Successful use of a second course of caplacizumab in relapsed thrombotic thrombocytopenic purpura
by: Jon Shaffer, et al.
Published: (2022-07-01)

Prolonged Exposure to Caplacizumab as Rescue Therapy in Refractory Immune Thrombotic Thrombocytopenic Purpura
by: Rodgers GM, et al.
Published: (2023-03-01)

EPIDEMIOLOGY, TREATMENT PATTERNS, AND CLINICAL OUTCOMES AMONG PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) IN THE UNITED STATES: AN ELECTRONIC HEALTH RECORDS ANALYSIS
by: Ayoade Adeyemi, et al.
Published: (2021-11-01)

Post Approval Experience with Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura at a Single Institution
by: Constantine N. Logothetis, et al.
Published: (2021-07-01)

P1664: IMPACT OF A PROTOCOL USING RITUXIMAB FOR PREVENTION OF RELAPSE IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP)
by: E. Marín Sánchez, et al.
Published: (2022-06-01)

Unmet needs in the management of immune‐mediated thrombotic thrombocytopenic purpura and the potential role of caplacizumab in the UK—A modified‐Delphi study
by: Marie Scully, et al.
Published: (2022-08-01)

Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management
by: Senthil Sukumar, et al.
Published: (2021-02-01)

P78 Thrombotic thrombocytopenic purpura (TTP) in an SLE patient successfully treated with plasma exchange, caplacizumab and rituximab
by: Branimir Anic, et al.
Published: (2024-03-01)

P1608: REAL-WORLD INSIGHTS ON THE MANAGEMENT OF IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP) WITH CAPLACIZUMAB IN BELGIUM
by: Daan Dierickx, et al.
Published: (2023-08-01)

Fatal cerebral hemorrhage in a patient with thrombotic thrombocytopenic purpura with a normal platelet count during treatment with caplacizumab
by: Kim Ditzel, et al.
Published: (2022-04-01)

Immune‐mediated thrombotic thrombocytopenic purpura in a Jehovah’s Witness – Effectiveness of incorporating extracorporeal immunoadsorption to caplacizumab, steroids and rituximab
by: Teresa Marta Cardesa‐Salzmann, et al.
Published: (2022-05-01)

P1609: CAPLACIZUMAB THERAPY IN OLDER PATIENTS (≥60 YEARS) WITH IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP). RESULTS OF THE SPANISH TTP REGISTRY
by: Javier DE LA Rubia, et al.
Published: (2023-08-01)

Does Caplacizumab for the management of thrombotic thrombocytopenic purpura increase the risk of relapse, exacerbation, and bleeding? An updated systematic review and meta‐analysis based on revised criteria by the International Working Group for thrombotic thrombocytopenic purpura
by: Niraj Neupane, et al.
Published: (2024-02-01)

Hypertension in patients with hereditary thrombotic thrombocytopenic purpura
by: Azra Borogovac, et al.
Published: (2020-07-01)

A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAPLACIZUMAB WITHOUT FIRST-LINE THERAPEUTIC PLASMA EXCHANGE IN ADULTS WITH IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA
by: Sriya GUNAWARDENA, MD, et al.
Published: (2023-10-01)

Relapse of Immune Thrombotic Thrombocytopenic Purpura Following Vaccination with COVID19 mRNA Vaccine
by: Katerina Pavenski
Published: (2021-07-01)

Clinical relapse of immune‐mediated thrombotic thrombocytopenic purpura following COVID‐19 vaccination
by: William Deucher, et al.
Published: (2022-01-01)

Outcomes and Costs in Patients with Immune Thrombotic Thrombocytopenic Purpura Receiving Front-Line Versus Delayed Caplacizumab: A US Hospital Database Study
by: Alix Arnaud MS, et al.
Published: (2024-03-01)

Thrombotic Thrombocytopenic Purpura
by: Nuchanat Nonsee, et al.
Published: (2015-02-01)

Long-term Kidney Outcomes in Patients With Acquired Thrombotic Thrombocytopenic Purpura
by: Dustin J. Little, et al.
Published: (2017-11-01)

Hereditary Thrombotic Thrombocytopenic Purpura
by: Sanober Nusrat, et al.
Published: (2023-10-01)

Vaccination and Thrombotic Thrombocytopenic Purpura
by: İrfan Yavaşoğlu
Published: (2020-08-01)

Idiopathic thrombotic thrombocytopenic purpura
by: Carmen Garrido Arce, et al.
Published: (2009-09-01)

Treatment of thrombotic thrombocytopenic purpura
by: Gennadii M. Galstyan, et al.
Published: (2021-07-01)

Diagnosis of thrombotic thrombocytopenic purpura
by: G. M. Galstyan, et al.
Published: (2020-12-01)

The Specificities of Thrombotic Thrombocytopenic Purpura at Extreme Ages: A Narrative Review
by: Adrien Joseph, et al.
Published: (2023-04-01)

5599228 PITFALLS IN DIAGNOSING THROMBOTIC THROMBOCYTOPENIC PURPURA IN SICKLE CELL DISEASE
by: D.A. TSITSIKAS, et al.
Published: (2023-04-01)

S305: PHASE 2 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER STUDY OF RECOMBINANT ADAMTS13 IN PATIENTS WITH IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA
by: Marie Scully, et al.
Published: (2023-08-01)

Understanding the Health Literacy in Patients With Thrombotic Thrombocytopenic Purpura
by: Leydi C. Velasquez Pereira, et al.
Published: (2020-08-01)